Scientific Poster
November 16, 2018

Validated next generation sequencing (NGS) assay for the characterization of the T-cell repertoire from RNA

GCP validated NGS assay
Activation of T-cells during cell-mediated immunity is initiated by the stimulation of the T- cell receptor (TCR) by major histocompatibility complex-antigen complexes. While the entire TCR chain is diverse, most of the diversity is concentrated in a hypervariable complementarity-determining region 3 (CDR3) loop, the center of the antigen-binding site for the TCR.  The frequency of a specific CDR3 sequence within the T-cell repertoire is a surrogate for the abundance of its corresponding T-cell clone. Deep sequencing of the TCR CDR3 region assists with resolving T-cell diversity, and, in oncology, detects specific clones or changes in clonality associated with anti-tumor immune responses.  Here, we have validated an RNA based TCRβ/γ next-generation sequencing assay for use with whole blood, peripheral blood mononuclear cells (PBMCs) and formalin-fixed paraffin-embedded (FFPE) tissues.

In this study, TCR analysis was performed using RNA or total nucleic acids derived from whole blood, PBMCs or tumor FFPE specimens.  The TCRβ/γ sequencing assay entailed gene specific cDNA synthesis, preparation of sequencing libraries, TCR gene specific amplification, sample barcoding and sequencing.  A 2x150 bp sequencing was performed and ≥2 million paired-end reads for each sample were obtained.  Data analysis was performed using Archer Analysis software.

Download our poster from SITC 2018 to learn more about our validated RNA-based NGS assay for the analysis of TCRβ/γ in whole blood, PBMC and FFPE specimens.

Related Services:
T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 15 Immune Landscape Signatures

Read More